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A B S T R A C T
Photodynamic therapy (PDT) is an emerging method to treat light-accessible malignancies. To increase speci-
ﬁcity and allow dose reduction, conjugates of photosensitizers (PS) with antibodies against tumor-associated
antigens have been developed for photoimmunotherapy (PIT). However, so far it is unclear whether cellular
internalization of these conjugates after binding aﬀects PIT eﬃcacy.
The use of low molecular weight llama single domain antibodies (VHHs, nanobodies) for PIT is preferred
above full size antibodies because of better tumor penetration. Therefore, we functionalized the VHH 7D12,
directed against the epidermal growth factor receptor (EGFR), with a PS (IRDye700DX). To assess the impact of
cellular internalization on activity, the VHHs were additionally conjugated to a cell-penetrating peptide
(VHH[PS]-CPP).
Here we show that upon illumination with near-infrared (NIR) light, both VHH[PS] and VHH[PS]-CPP con-
jugates speciﬁcally induce cell death of EGFR expressing cancer cell lines and of EGFR-expressing cells derived
from surgically obtained ascites from patients with high-grade serous ovarian cancer. However, VHH[PS] con-
jugates were signiﬁcantly more eﬀective compared to internalizing VHH[PS]-CPP suggesting that cell surface
association is required for optimal therapeutic activity.
1. Introduction
Photodynamic therapy (PDT) is a method to induce cell death
through administration and activation of a photo-sensitizer (PS). When
activating the PS with light of the appropriate wavelength, the PS is
transferred from its ground state into an excited triplet state [1] that
can return to the ground state via transmitting its energy to molecular
oxygen, leading to the formation of reactive oxygen species (ROS). In
general, these ROS are formed through type II photo-oxidative reactions
that result in the formation of singlet oxygen, a highly toxic and short-
lived radical that induces peroxidation and breakdown of lipids, pro-
teins and nucleic acids [2].
For tumors that are amenable for local light application, PDT has a
number of advantages as compared to other therapies. It is less invasive
than surgery and, because of its local character, more selective than
chemotherapy. Furthermore, the direct cell killing eﬀects of PDT pre-
vent development of resistance, as is seen with chemotherapy and most
targeted therapies [3] and may also induce a vaccination eﬀect because
PDT-induced necrotic cell death releases neo-epitopes that may chal-
lenge the immune system [4]. PDT has been tested in clinical trials for
cancer of the bladder, skin, head and neck. Various PSs are now ap-
proved as PDT drugs [5].
There are, however, some issues with PDT that still need to be
solved. Currently used PSs suﬀer from low water solubility and dark
toxicity. To enhance solubility, signiﬁcant eﬀorts have been made in
engineering drug delivery systems that allow tumor-speciﬁc targeting
of PS [6–12]. Even though antibodies are highly potent targeting ve-
hicles, antibody-PS conjugates for photoimmunotherapy (PIT) [13,14]
have the disadvantage that they circulate for weeks, increasing the risk
of dark toxicity and phototoxicity in light-exposed skin [15]. To reduce
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T
circulation time, conjugates of PS with small-sized recombinant llama
antibodies (VHHs) have been used to induce epidermal growth factor
receptor (EGFR)-dependent cell death [14,16]. The small size of these
delivery systems also allows faster tumor accumulation and better
tissue penetration as compared to full-size antibodies, and improves the
carrier-to-drug molecular weight ratio [17].
The half-life of singlet-oxygen in biological systems is< 40 ns, re-
stricting its toxic action radius to< 20 nm [2]. Studies using photo-
sensitizers with diﬀerent physicochemical properties that behave dif-
ferently with respect to cell uptake have shown that intracellular
localization greatly inﬂuences the cellular response to light-induced
activation. PSs that localize to the mitochondria or cytoplasm are de-
scribed to induce apoptosis, while necrosis is induced when the plasma
membrane is the site of action [18,19]. Furthermore, more eﬃcient
membrane binding and membrane photooxidation increases photo-
toxicity of the PS [20].
Next to relying on internalization of targeted receptors, inter-
nalization of VHHs can also be triggered by conjugation to cell-pene-
trating peptides (CPPs) [21], a class of peptides that mediate cellular
uptake of molecules that otherwise do not enter the cell [22]. Con-
jugation of the anti-EGFR VHH 7D12 to the CPP hLF, derived from
human lactoferrin [23], endows the VHH with the capacity to enter the
cell [24].
To investigate how the eﬃcacy of PIT is inﬂuenced by the sub-
celullar localization of the PS we used a site-selective bioconjugation
protocol to functionalize the EGFR targeting VHH 7D12 [25,26] with
the PS IRDye700DX. Using sortase A transpeptidation we conjugated
hLF to VHH 7D12[PS], yielding 7D12[PS]-hLF. We then investigated the
eﬃcacy of both constructs on light-induced cell death and show that the
CPP-free non-internalizing variant is more active in inducing cell death.
2. Material and methods
2.1. Cell culture
Human epidermoid carcinoma A431 cells, carrying an ampliﬁcation
of the EGFR gene [27], human high grade astrocytoma E98 cells
without EGFR expression [28] and human ovarian adenocarcinoma SK-
OV-3 cells with intermediate EGFR expression [29] were cultured in
Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Lonza, Basel, Switzer-
land) supplemented with 10% fetal calf serum (FCS) (Gibco, Thermo
Fisher Scientiﬁc, Waltham, MA, USA) and 40 µg/ml gentamycin (Cen-
trafarm, Etten-Leur, The Netherlands). Cells were cultured at 37 °C in
5% CO2 in a humidiﬁed atmosphere.
2.2. Sortase A expression
E. coli ER2566 cells transformed with the plasmid pGBMCS-SortA,
encoding His6-tagged sortase A with an N-terminal deletion of 59 amino
acids [30] (Addgene, Cambridge, MA, USA, plasmid #21931) were
grown to log phase at 37 °C, and protein expression was induced with
1.0 mM isopropyl β-D-thiogalactoside (IPTG, Serva, Heidelberg, Ger-
many) at 30 °C for 3 h. Cells were harvested, resuspended in ice-cold
50mM Tris pH 8.0/300mM NaCl containing a protease inhibitor
cocktail (Roche, Basel, Switzerland) and lysed by sonication using a
Bandelin Sonopuls HD2070 sonicator (Bandelin electronic GmbH & Co,
Berlin, Germany). After centrifugation the supernatant was incubated
with Ni-NTA sepharose (IBA, Goettingen, Germany) in 50mM phos-
phate pH 7.4/500mM NaCl for 1 h at 4 °C. After washing, His6-tagged
sortase A was eluted from the beads with 500mM imidazole. The eluate
was dialyzed against 50mM Tris pH 7.5/150mM NaCl in a 3.5 kDa
dialysis membrane (Spectrum Labs, Los Angeles, CA, USA). Protein
purity was analyzed by SDS-PAGE gel electrophoresis under reducing
conditions and liquid chromatography mass spectrometry (LC–MS,
Shimadzu HPLC and Thermo Finnigan LCQ Fleet) on a C4 column.
Protein concentration was determined by absorbance at 280 nm using
the Nanodrop spectrophotometer (LI-COR, Lincoln, NE, USA).
2.3. VHH expression
The cDNA encoding anti-EGFR VHH 7D12 (a gift from Paul van
Bergen en Henegouwen, Utrecht University, The Netherlands) was re-
cloned into the vector pHENIX-C-LPETG-His8-Vsv, resulting in 7D12-C-
LPETG-His8-Vsv, the cysteine providing a handle for maleimide con-
jugation, LPETG being a sortase A consensus recognition sequence and
the His8-Vsv tag allowing Ni-based puriﬁcation and Vsv-based detec-
tion. 7D12-C-LPETG-His8-Vsv expression was induced via standard
methods in E. coli strain TG1. Cells were harvested by centrifugation at
2830g for 20min at 4 °C, resuspended in ice cold Tris/EDTA/sucrose
(TES) buﬀer (200mM Tris pH 8.0/0.5 mM EDTA/20% w/v sucrose/
protease inhibitor cocktail) and incubated for 20min on ice, followed
by centrifugation (4424g, 20min, 4 °C). The supernatant was collected
and the pellet was resuspended in TES buﬀer supplemented with 15mM
MgSO4, and incubated on ice for 20min. After centrifugation, both
supernatants were pooled and protein was puriﬁed with Ni-NTA se-
pharose as described for sortase A.
2.4. IRDye700DX conjugation
All steps involving IRDye700DX were performed in the dark. 7D12-
C-LPETG-His8-Vsv was incubated with 20mM tris(2-carboxyethyl)
phosphine (TCEP) (Thermo Fisher Scientiﬁc, Waltham, MA, USA) for
15min at room temperature to reduce the free thiol group of the cy-
steine. TCEP was removed in a 10 kDa MWCO centrifugal unit (Amicon,
Millipore, Billerica, MS, USA) employing 5 washing cycles with 20mM
phosphate pH 7.0/150mM NaCl/5mM EDTA. Maleimide-PEG4-DBCO
(Jena Bioscience, Jena, Germany, 10mM stock in DMF) was allowed to
react for 2 h at room temperature in a thermoshaker at 450 rpm with
7D12-C-LPETG-His8-Vsv in a 3:1molar ratio, yielding 7D12-C[DBCO]-
LPETG-His8-Vsv. Excess maleimide-PEG4-DBCO was removed by ﬁlter
centrifugation in a 10 kDa MWCO centrifugal unit employing 4 washing
cycles with 50mM Tris pH 7.5/150mM NaCl. The protein conjugate
was analyzed by LC–MS, and protein concentration was determined by
ultraviolet absorbance at 309 nm using the Nanodrop spectro-
photometer.
In parallel, IRDye700DX-NHS (LI-COR, Lincoln, NE, USA from now
on referred to as PS-NHS) was incubated with H2N-PEG3-N3 (Jena
Bioscience, Jena, Germany) in a 3:1 molar ratio in 100mM phosphate
buﬀer pH 8.6/150mM NaCl for 7 h at RT in a thermoshaker at 450 rpm,
yielding PS-N3. Subsequently 7D12-C[DBCO]-LPETG-His8-Vsv was in-
cubated with PS-N3 in a 1:2molar ratio o/n at RT in a thermoshaker at
450 rpm, yielding 7D12-C[PS]-LPETG-His8-Vsv. This conjugate was
puriﬁed from unconjugated PS-N3 by centrifugation in a 10 kDa MWCO
centrifugal unit employing 4 washing cycles with 50mM Tris pH 7.5/
150mM NaCl. The protein was analyzed by SDS-PAGE gel electro-
phoresis under reducing conditions and with electrospray ionization
time-of-ﬂight mass spectrometry (ESI-ToF) on a JEOL AccuTOF-CS
(JEOL, Tokio, Japan). Protein concentration was determined by mea-
suring absorbance at 689 nm (ε=165,000M−1 cm−1, assuming 1:1
complete labeling) using the Nanodrop spectrophotometer.
2.5. Functionalization of 7D12-C[PS]-LPETG-His8-Vsv with hLF
GGG-hLF or GGG-hLF(Fluo] (synthesized by EMC microcollections,
Tübingen, Germany) was dissolved in 50mM HEPES pH 8.0 at
5–10mM, to ensure intramolecular disulﬁde bridge formation that is
required for CPP activity [31]. The carboxyﬂuorescein moiety was
coupled to a C-terminal lysine residue. Subsequently sortase A (80 µM
ﬁnal concentration) and GGG-hLF (100 µM ﬁnal concentration) were
added to 7D12-C[PS]-LPETG-His8-Vsv (20 µM ﬁnal concentration) in
50mM Tris pH 7.5/150mM NaCl/10mM CaCl2. The sortase reaction
was allowed to proceed for 5 h at 30 °C in a thermoshaker at 450 rpm,
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after which the reaction mixture was incubated with pre-washed Ni-
NTA sepharose beads to remove the His6-tagged sortase A, G-His8-Vsv
and unreacted 7D12-C[PS]-LPETG-His8-Vsv. Excess GGG-hLF was re-
moved from the Ni-NTA agarose supernatant by ﬁltration in a 10 KDa
MWCO centrifugal unit employing 6 cycles against 20mM phosphate
pH 7.5/500mM NaCl. Purity and concentration of the VHH conjugate
were analyzed by SDS-PAGE gel electrophoresis and ESI-ToF. Protein
concentrations were determined by measuring absorbance at 689 nm
using the Nanodrop spectrophotometer.
2.6. Fluorescein labeled constructs for confocal microscopy applications
For confocal microscopy applications, 7D12 constructs directly la-
beled with ﬂuorescein were produced. 7D12-C-LPETG-His8-Vsv was
reduced with 20mM TCEP as described above. Then ﬂuorescein-5-
maleimide (Thermo Fisher Scientiﬁc, Waltham, MA, USA, 10mM stock
in DMF) was reacted with reduced 7D12-C-LPETG-His8-Vsv in a
3:1 molar ratio in 20mM phosphate pH 7.0/150mM NaCl/5mM EDTA
for 2 h at RT in a thermoshaker at 450 rpm. Excess ﬂuorescein-5-mal-
eimide was removed by ﬁltration in a 10 kDa MWCO centrifugal unit
employing 4 washing cycles with 50mM Tris pH 7.5/150mM NaCl.
7D12-C-LPETGGG-hLF[Fluo] was prepared using sortase A as described
above, using 50 µM sortase A, 50 µM GGG-hLF[Fluo] and 20 µM 7D12-C-
LPETG-His8-Vsv in 50mM Tris pH 7.5/150mM NaCl/10mM CaCl2. The
product was puriﬁed using Ni-NTA sepharose and ﬁlter centrifugation
as described. Protein conjugates were analyzed by SDS PAGE gel elec-
trophoresis under reducing conditions and LC-MS. Protein concentra-
tion was determined by measuring absorbance at 494 nm
(ε=75,000M−1 cm−1, assuming 1:1 complete labeling) using the
Nanodrop spectrophotometer.
2.7. Cell uptake assays with confocal microscopy
Cellular uptake of the diﬀerent ﬂuorescein-labeled 7D12 conjugates
was examined with confocal microscopy on a TCS SP5 microscope
(Leica Microsystems, Mannheim, Germany) equipped with an HCX PL
APO 63×1.2 water immersion lens. During imaging, cells were
maintained at 37 °C. The 488 nm laser line of the argon laser was used
for excitation and emission was collected between 500 and 550 nm.
A431, E98 and SK-OV-3 cells (30,000, 50,000 and 30,000 cells per well,
respectively) were plated in 8-well Lab-Tek borosilicate coverglass
chambers (NUNC, Thermo Fisher Scientiﬁc, Waltham, MA, USA) and
allowed to adhere and proliferate for 48 h. Then cells were incubated
for 30min at standard culture conditions in 200 µl phenol red-free
RPMI/10% FCS, supplemented with 2 µM of 7D12-C[Fluo]-LPETG-His8-
Vsv, 7D12-C-LPETGGG-hLF[Fluo], or GGG-hLF[Fluo]. Subsequently, cells
were washed twice with phenol red-free RPMI/10% FCS containing
20mM HEPES and were imaged by confocal microscopy. Acidic pH in
lysosomes reduces ﬂuorescein ﬂuorescence. To investigate if this eﬀect
lead to an underestimation of 7D12-hLF[Fluo] uptake, we treated cells
with 65 μM chloroquine, which increases the lysosomal pH and thereby
enhances ﬂuorescein ﬂuorescence [32]. The samples were imaged once
more and, to quench extracellular ﬂuorescence, 0.4% trypan blue
(Sigma Aldrich, Saint Louis, MO, USA) was added to the wells before
imaging for a third time [33].
2.8. Study of cell uptake mechanism with confocal microscopy
To detect clathrin-dependent endocytosis, cells were co-incubated
with the constructs as described above and 100 µg/ml transferrin-Alexa
Fluor 633 (Life Technologies, Thermo Fisher Scientiﬁc, Waltham, MA,
USA). After 30min, the cells were washed and colocalization of trans-
ferrin and the constructs was detected by confocal microscopy.
Fluorescein was excited with the argon laser at 488 nm and emission
was detected between 500 and 550 nm. Alexa Fluor 633 was excited
with the 633 nm helium-neon laser and ﬂuorescence detected between
650 and 715 nm.
2.9. In vitro PDT assays with adherent cell cultures
A431, E98 and SK-OV-3 cells were cultured in clear 96-well plates
(Costar, Greiner-Bio One, Essen, Germany). At 80% conﬂuency cells
were incubated for 30min with diﬀerent concentrations of 7D12-C[PS]-
LPETG-His8-Vsv, 7D12-C[PS]-LPETGGG-hLF or equimolar concentra-
tions of PS alone in DMEM/10% FCS. Controls were incubated with
DMEM/10% FCS only. Cells were washed twice with warm DMEM/
10% FCS. Immediately after washing, plates were illuminated with
100mW/cm2 for 600 s, reaching a total light dose of 60 J/m2, using a
standardized light emitting diode device (690 ± 10 nm) as described
in [34]. To determine dark toxicity, cells were incubated with the
highest used concentration of the conjugates without subsequent illu-
mination. After overnight incubation a sulforhodamine-B-assays (SRB)
assay was performed as described in [35] to determine total protein
content. Results were expressed as cell viability relative to controls
(untreated illuminated cells). Half maximal inhibitory concentration
(IC50) of the various conjugates were determined in GraphPad Prism
5.02 (LaJolla, CA, USA).
To examine selectivity of PDT-induced cytotoxicity with the dif-
ferent conjugates, 5× 105 cells were labeled with DiO (A431 and SK-
OV-3) or DID (E98) dye (Life technologies, Thermo Fisher Scientiﬁc,
Waltham, MA, USA) according to manufacturers protocol. Mixtures of
A431, E98 and SK-OV-3 cells were plated and subjected to PDT as de-
scribed above. Immediately, 2 h and 16 h after illumination cells were
incubated with 1 µg/ml propidium iodide (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) in PBS for 15min. Cells were visualized with the
EVOS FL digital inverted ﬂuorescence microscope (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) using the RFP LED light cube
(Propidium Iodide), the GFP LED light cube (DiO labeled cells) and the
Cy5 LED light cube (DiD labeled cells).
2.10. Mechanism of cell death
To check if apoptotic cell death was induced by 7D12-C[PS] con-
jugates, cells were treated with 15 nM 7D12-C[PS] conjugates and illu-
minated as described. Immediately, 2 h and 20 h after illumination cells
were incubated with 1:250 Annexin-V-Alexa488 (Life Technologies,
Thermo Fisher Scientiﬁc, Waltham, MA, USA) and 1 µg/ml propidium
iodide in 10mM HEPES pH 7.4/140mM NaCl/2.5 mM CaCl2 to stain
apoptotic and dead cells, respectively. Stained cells were visualized
with the EVOS. As a positive control, cells were treated with 2 µM
staurosporin for 4 h at 37 °C
Furthermore, extracts of treated cells 2 h and 4 h after illumination
and of staurosporin-treated control cells were made with RIPA buﬀer
(#9806, Cell Signaling Technology, Danvers, MA, USA). 20 µg of total
protein was run on an 8% SDS-PAGE gel, and electroblotted on a ni-
trocellulose membrane (GE healthcare, Little Chalfont, USA). Blots
were stained with rabbit-anti-cleaved-Caspase-3 (Asp175) (1:1000,
#9661, Cell Signaling Technology, Danvers, MA, USA) and mouse-anti-
GAPDH. Blots were visualized on the Odyssey scanner.
2.11. In vitro PDT assays with spheroids
Because 3D cell cultures better recapitulate clinical tumors than
adherent 2D cell cultures, we grew SK-OV-3 cells as tumor spheroids.
To this end, 96-well round bottom culture plates were coated with
100 µl/well 1% agarose (Sigma Aldrich, Saint Louis, MO, USA) in
DMEM/F12 medium (Gibco, Thermo Fisher Scientiﬁc, Waltham, MA,
USA). SK-OV-3 cells (30,000/well) were seeded in 100 µl DMEM/F12
medium containing 0.3% BSA. Three days after seeding, the spheres
were incubated for 30min or 1 h at 37 °C in DMEM/10% FCS and
120 nM 7D12-C[PS]-LPETG-His8-Vsv, 7D12-C[PS]-LPETGGG-hLF, PS
alone or medium only. After washing with DMEM/10% FCS spheres
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were illuminated with a 60 J/m2 total light dose. After overnight in-
cubation at 37 °C, spheres were ﬁxed in Uniﬁx (Klinipath, Duiven, The
Netherlands) at RT, and embedded in agar. 4 µM sections were stained
with hematoxylin and eosin.
2.12. Ex vivo PDT assays with clinical ascites samples
All experiments with patient materials were performed according to
institutional guide lines. To examine whether PIT with our conjugates
could be an option for treatment of ovarian cancer we tested our con-
structs on cells, freshly derived from malignant ascites of patients di-
agnosed with high-grade serous ovarian carcinoma. Ascites was ﬁltered
through a 70 µm cell strainer. Nucleated cells were isolated by cen-
trifugation on Ficoll, according to the manufacturer’s instructions
(Sigma Aldrich, Saint Louis, MO, USA) and cultured in RPMI/10% FCS/
40 μg/ml gentamycin. For PDT experiments, cells were seeded at
10,000 cells per well in a 96-well plate and grown until > 50% con-
ﬂuency. After incubation with 15 nM of 7D12-C[PS]-LPETG-His8-Vsv,
7D12-C[PS]-LPETGGG-hLF or PS alone for 30min, cells were illumi-
nated with 60 J/m2 total light dose. The next day, cell viability was
determined using the SRB assay. In parallel experiments, ascites-de-
rived cells were incubated with 15 nM of the diﬀerent 7D12-C[PS]
conjugates for 30min, illuminated and incubated overnight. The next
day, cells were incubated with either 1 µg/ml cetuximab for 20min and
goat-anti-human Alexa488 (1:200 Thermo Fisher Scientiﬁc, Waltham,
MA, USA) for 20min to verify EGFR expression, or mouse-anti-EpCAM
(1:200 Abcam, Cambridge, UK ab7504) and donkey-anti-mouse
Alexa488 (1:200 Thermo Fisher Scientiﬁc, Waltham, MA, USA) to
verify EpCAM expression, and with 1 µg/ml propidium iodide (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) to visualize the dead cells.
Propidium iodide and bound antibodies were visualized using the EVOS
microscope.
2.13. Statistics
Experiments were performed at least in duplicate, and within ex-
periments all measurements were done in triplicate. IC50 values were
determined in Graphpad Prism and statistical signiﬁcance was checked
with a Student’s T-test. To check for signiﬁcance of other data a one-
way ANOVA with post hoc Bonferroni was performed in Graphpad
Prism; *= p < .05, **= p < .01, ***=p < .001.
3. Results and discussion
3.1. Preparation and characterization of 7D12-C[PS] conjugates
Targeted PDT of cancers requires high tumor selectivity and speci-
ﬁcity, concomitant with a lack of dark toxicity. Approaches that im-
prove tumor selectivity of the PS by conjugation to antibodies still have
major drawbacks due to the long circulation half-lives of these con-
jugates, and poor penetration of these large constructs into poorly
perfused tumor areas. To tackle these problems, smaller targeting
moieties like VHHs are interesting alternative PS carriers. Here, the
anti-EGFR VHH 7D12 was used as a clinically relevant model VHH to
examine how subcellular localization of PSs aﬀects PDT eﬃcacy. It was
published before that 7D12-IRdye700DX conjugates can be prepared
successfully via NHS-based conjugation to lysines [14]. This approach
however, carries a risk of overlabeling of lysines that are involved in
antigen binding, resulting in reduced aﬃnity. Also, this procedure
yields a heterogeneous mixture of VHHs, containing a fraction of un-
labeled VHHs that may act as competitor for the labeled ones. We
therefore chose to perform a site-selective reaction at an introduced
cysteine at the carboxyterminus (Fig. 1A). Because IRDye700DX was
not available as a maleimide conjugate at the time of this study, we ﬁrst
coupled a dibenzocyclo-octyn (DBCO)-functionality to the VHH and an
azide functionality to the PS. This enabled us to use the highly speciﬁc
and bio-orthogonal click reaction between azide and DBCO [36]. 7D12-
C[DBCO]-LPETG-His8-Vsv and 7D12-C[PS]-LPETG-His8-Vsv were pro-
duced successfully as veriﬁed with SDS-PAGE electrophoresis (Fig. 1B)
and LC-MS (Fig. 1C). LC-MS veriﬁed conjugation of only one mal-
eimide-DBCO and PS molecule per VHH, as we have seen before for
maleimide-ﬂuorescein [37]. This method is generally applicable to all
VHHs, as long as these do not carry unpaired cysteines in the com-
plementarity determining region, and since all reactions occur distant
from the VHHs’ antigen binding site, this approach is predicted to retain
VHH aﬃnity.
By employing sortase-A-mediated ligation of GGG-hLF (Fig. 1D), we
successfully produced 7D12-C[PS]-LPETGGG-hLF (Fig. 1B and E). Be-
cause we did not have lasers compatible for detection of IR-
Dye700DX–ﬂuorescence with confocal microscopy, we also prepared
ﬂuorescein labeled variants 7D12-C[Fluo]-LPETG-His8-Vsv and 7D12-C-
LPETGGG-hLF[Fluo].
3.2. Cellular binding and uptake of 7D12 conjugates
Previous research has shown that hLF is taken up by endocytosis at
concentrations below 10 µM [23], and that functionalization of 7D12
with hLF causes increased internalization of the VHH [24]. Here we
conﬁrmed these patterns of cellular uptake in A431 and SK-OV-3 cells
(Fig. 2). Cells were incubated with the conjugates at a concentration of
2 μM at which little vesicular uptake of hLF alone was observed (sup-
plementary Fig. 1A). 7D12-C[Fluo]-LPETG-His8-Vsv showed a pre-
dominant membrane staining whereas for 7D12-C-LPETGGG-hLF[Fluo]
membrane staining was weaker and a more pronounced vesicular
ﬂuorescence was observed. SK-OV-3 cells showed very weak membrane
staining after incubation with 7D12-C[Fluo]-LPETG-His8-Vsv, but after
incubation with 7D12-C-LPETGGG-hLF[Fluo] intracellular vesicular
staining was observed, which was more clearly visible after quenching
extracellular ﬂuorescence with trypan blue (Fig. 2). No binding to or
uptake in E98 was observed for both 7D12 conjugates (supplementary
Fig. 1B). This latter ﬁnding further conﬁrmed that cell association was
primarily VHH and not hLF driven.
It is generally accepted that CPPs lack cell line selectivity, however,
such experiments are typically conducted at medium micromolar con-
centrations [38]. The dissociation constant of the binding of hLF to cell
surface glycosaminoglycans is in the low micromolar range [31], while
reported Kd values of 7D12 binding to cell-associated EGFR is in the
order of 10–20 nM [14,17,26]. Cell ELISAs, performed at 4 °C to study
binding in the absence of internalization, conﬁrmed high aﬃnity
binding of 7D12-C[PS]-LPETG-His8-Vsv and 7D12-C[PS]-LPETGGG-hLF
to EGFR overexpressing A431 cells (Kd= 11.85 ± 1.203 and
25.53 ± 2.514 nM, respectively; not shown). At the low micromolar
and subnanomolar concentrations that we employed in the uptake and
PDT assays, respectively, binding of the diﬀerent conjugates is therefore
expected to be determined by the 7D12 moiety, rather than hLF. This
ﬁnding has important implications for in vivo applications of CPP-based
strategies. Except for those tissues that show a high propensity for CPP
uptake [39], uptake of VHH-CPP conjugates is directed by the presence
of EGFR. In this case, the CPP module is a modulator of subcellular
traﬃcking rather than an unspeciﬁc driver of uptake.
3.3. hLF mediated uptake of 7D12 is initiated by clathrin mediated
endocytosis
In previous work we showed that 7D12-LPETGGG-hLF[Fluo] induces
internalization of EGFR [24], which can be initiated by clathrin medi-
ated endocytosis (CME) and/or clathrin independent endocytosis [40].
To investigate if the 7D12-LPETGGG-hLF[Fluo] induced internalization
of EGFR is clathrin-dependent we incubated A431 cells with the various
CPP constructs in the presence of transferrin-Alexa633 (Fig. 3). Both
7D12-LPETGGG-hLF[Fluo] and hLF[Fluo] but not 7D12[Fluo]-LPETG-His8-
Vsv induced vesicular uptake as seen by enhanced transferrin staining
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that colocalized with the hLF-containing constructs.
3.4. PIT eﬃcacy of 7D12-C[PS] constructs in adherent cell cultures
Cell killing assays showed that 7D12-C[PS] conjugates were very
potent and speciﬁc PDT agents, without inducing dark toxicity (Fig. 4A
and C). Incubation with PS alone, followed by illumination did not
induce cell killing under the conditions used (Fig. 4B). Although the
7D12-C[PS] conjugates that we produced via a two-step click reaction
contained only one PS per VHH, these induced EGFR-speciﬁc cell death
very eﬃciently, with an IC50 value for 7D12-C[PS]-LPETG-His8-Vsv on
A431 cells of 87.8 ± 4.3 pM after NIR light illumination with 60 J/m2.
Fig. 1. Analytical characterization of the conjugates. (A) Scheme of bio-orthogonal conjugation of azide-functionalized PS to the DBCO-functionalized VHH. (B) Upper panel: coomassie
brilliant blue (CBB) stained SDS-PAGE gel of the reaction products after conjugation of the N3-PEG3-PS to 7D12-C[DBCO]-LPETG-His8-Vsv (1: 7D12-C-LPETG-His8-Vsv, 2: 7D12-C[DBCO]-
LPETG-His8-Vsv, 3: 7D12-C[PS]-LPETG-His8-Vsv before column puriﬁcation, 4: 7D12-C[PS]-LPETG-His8-Vsv after column puriﬁcation). Lower panel: visualization of the SDS-page gel at
680 nm before coomassie staining (left) and of the coomassie-stained gel (right) with reaction products and controls of the sortase A conjugation to functionalize 7D12-C[PS]-LPETG-His8-
Vsv with GGG-hLF (5: 7D12-C[PS]-LPETG-His8-Vsv, 6: Sortase A /7D12-C[PS]-LPETG-His8-Vsv after 5 h incubation at 30 °C, 7: the ﬁnal product 7D12-C[PS]-LPETGGG-hLF after Ni-NTA
puriﬁcation). (C) LC-MS characterization of TCEP-reduced 7D12-C-LPETG-His8-Vsv (upper, observed 17,837 Da, calculated 17837.6 Da) and 7D12-C[DBCO]-LPETG-His8-Vsv (lower,
observed 18,511 Da, calculated 18512.4 Da). The left graphs show the total mass spectra, the right graphs show the deconvoluted spectra. (D) Scheme of site speciﬁc conjugation of VHH-
C[PS]-LPETG-His8-Vsv to GGG-hLF with sortase A. (E) ESI-ToF characterization of 7D12-C[PS]-LPETG-His8-Vsv (upper graphs, observed 20,495 Da, calculated 20569.7 Da) and 7D12-C[PS]-
LPETGGG-hLF (lower graphs, observed 20,724 Da, calculated 20720.2 Da). The left graphs show the total mass spectra, the right graphs the deconvoluted spectra.
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Fig. 3. Induction of clathrin-dependent endocytosis by hLF conjugates. A431 cells were incubated for 30min with 2 µM of the CPP constructs in the presence of transferrin-Alexa633. The
scale bar denotes 10 µm.
Fig. 2. Cell binding and uptake of the constructs. A431 and SK-OV-3 cells were incubated with 2 µM of 7D12-C[Fluo]-LPETG-His8-Vsv and 7D12-C-LPETGGG-hLF[Fluo] and imaged by
confocal laser scanning microscopy before and after quenching ﬂuorescence from extracellular located ﬂuorescein with trypan blue (TB). The scale bar denotes 10 µm.
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Interestingly, conjugates containing hLF were less eﬀective with an
IC50 of 234.1 ± 122.7 pM (p= .3556) (Fig. 4C). In the intermediate
EGFR expressing SK-OV-3 cells, similar diﬀerences were observed be-
tween 7D12-C[PS]-LPETG-His8-Vsv (IC50= 705.1 ± 164 pM) and the
internalizing variant 7D12-C[PS]-LPETGGG-hLF (IC50=2680 ±
323.5 pM) (p= .0055). Interestingly, in previous reports it was de-
monstrated that VHH-PS conjugates with higher aﬃnity for EGFR had
higher PIT eﬃcacy and it was suggested that increased internalization
due to higher aﬃnity was responsible for increased photosensitivity
[14]. Furthermore, internalizing antibody-PS conjugates were shown to
be more eﬀective in PIT than non-internalizing antibody-PS [41]. Our
data, however, show that increased cell surface association is a more
important determinant. Interestingly, no phototoxicity was induced in
non-EGFR expressing E98 cells in line with the low cell binding capacity
mediated by the CPP alone.
To further assess the selectivity of the 7D12-C[PS] conjugates, co-
culture experiments with A431, E98 and SK-OV-3 were performed.
These cell types were distinguished by pre-labeling them with diﬀerent
membrane associated dyes. Labeled and dead cells were visualized
immediately, 2 h and 16 h after illumination (Fig. 4D and supplemen-
tary Fig. 2). Only EGFR expressing cells were killed after PDT (Fig. 4D).
No cell death was observed in the controls (no PS-conjugates added,
data not shown). Parallel experiments with monocultures of the cells
showed that cell death was induced immediately after illumination for
the A431 cells, and after 2–16 h for the SK-OV-3 cells (supplementary
Fig. 3). The cell death of A431 immediately after PDT suggested that
necrosis was induced. Neither A431 and SK-OV-3 cells were stained
with Annexin-V (not shown), and they did not induce caspase-3 de-
pendent apoptosis at 4 h after PDT, which further indicates that cells
indeed died by necrosis (supplementary Fig. 4). Unconjugated IR-
Dye700DX did not lead to phototoxicity in all used cell types, in
agreement with previous studies, and did not display dark toxicity. This
Fig. 4. Phototoxicity induced by the constructs in adherent cells. (A) Absence of dark toxicity of 7D12-C[PS] constructs (45 nM) and PS alone (45 nM for 10 J/m2 and 15 nM for 60 J/m2)
and (B) toxicity of non-targeted PS with illumination. Results are shown as survival relative to untreated cells. (C) The relative cell viability after incubation with various concentrations of
7D12-C[PS] constructs and illumination with a 60 J/m2 total light dose was also determined in SRB assays. (D) Co-cultures ﬂuorescently labeled with DiDyes were incubated with 15 nM
7D12-C[PS] constructs and illuminated with a 60 J/m2 total NIR light dose. Two hours after illumination cells were imaged. Controls were illuminated only.
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Fig. 5. Phototoxicity induced by the constructs in ovarian carcinoma spheroids and clinical ascites. (A) SK-OV-3 spheres were incubated with 120 nM of the 7D12-C[PS] constructs or
controls and illuminated with a NIR light dose of 60 J/m2. Sections of agar-embedded treated or control SK-OV-3 spheroids were stained with hematoxylin and eosin. Note that the outer
layer of cells have picnotic nuclei, visualized more clearly in the enlarged insert. (B+C) Cultured cells from clinical ascites were incubated with 15 nM of the various 7D12-C[PS]
constructs and illuminated with a total NIR light dose of 60 J/m2. Dead cells and (B) EGFR or (C) EpCAM expressing cells in an ascites derived cell culture after PDT were imaged. Note the
weaker signal of cetuximab in the dead 7D12-C[PS] treated samples compared to the live cells in the controls. (D) The percentage of cell viability in multiple cultures was determined with
SRB assays. *= p < .05, **= p < .01.
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makes it a suitable compound for targeted PDT [42].
3.5. Eﬃcient PIT with ovarian carcinoma SK-OV-3 spheroids and EGFR
positive cells in clinical ascites
To assess eﬀectiveness of the conjugates in a cellular model with
more resemblance to the in vivo tumor situation, conjugates were in-
cubated with SK-OV-3 spheroids. PIT with SK-OV-3 spheroids showed
eﬃcient cell killing after incubation with 120 nM of the 7D12-C[PS]-
LPETG-His8-Vsv construct and a light dose of 60 J/m2, illustrated by the
majority of cells with picnotic nuclei in the HE stained sections, and
only a minority of cells in the centre that appeared viable (Fig. 5A,
enlargement in insert). In the 7D12-C[PS]-LPETGGG-hLF treated cells,
also dead cells with picnotic nuclei were observed but to a lesser extent.
Control spheres showed only viable cells, indicating that cell death also
in the centre is due to penetration of the VHH conjugates into the
spheroid.
Finally, cells derived from clinical ascites from women with stage III
or IV high-grade serous ovarian carcinoma (n= 7) were incubated with
15 nM 7D12-C[PS] constructs and illuminated with 60 J/m2 NIR light.
Phototoxicity was restricted to the EGFR-positive subpopulation of
cells, as could be observed by costainings for dead cells (propidium
iodide) and EGFR (Cetuximab). The absence of costaining for dead cells
and a population of cells positive for another tumor marker (EpCAM)
indicated selectivity for EGFR (Fig. 5C). SRB assays after incubation
with 7D12[PS] constructs and illumination showed signiﬁcant decreases
in overall cell viability compared to controls (P < .001 and P < .03
for 7D12-C[PS]-LPETG-His8-Vsv and 7D12-C[PS]-LPETGGG-hLF, respec-
tively (Fig. 5D). The survival of about 60–70% of the cells is in agree-
ment with the notion that ascites also contain numerous non-EGFR-
expressing cells (as shown in Fig. 5C) that are expected to survive the
treatment.
With the use of optical ﬁbers NIR light can be delivered to otherwise
inaccessible tumors, as has been shown for peritoneal metastasis of
ovarian cancer using Verteporﬁn [43]. In addition, peroperative
ﬂuorescent image-guided surgery is gaining momentum [44] and could
be very well extended with compounds comparable to those described
here.
4. Conclusion
Targeted PDT is a rapidly increasing ﬁeld which promises to become
of great importance for the treatment of light-accessible malignancies.
Targeted light-induced cancer cell death has great advantages as com-
pared to currently applied targeted treatments which mostly only delay
progression of cancers, giving these ample time to develop resistance.
We here describe the construction of a highly deﬁned VHH-PS via a
controlled bioconjugation method that is easily applicable to other
VHHs. Despite the fact that every VHH carries only one PS molecule,
these constructs are highly selective and speciﬁc, requiring very low
concentrations to induce eﬃcient cell killing via necrosis. In 3D-
spheroid models, eﬃcient cell killing was observed, indicating that
these low-molecular weight constructs have good tissue penetrating
properties. Furthermore, we show that conjugation to a CPP endows the
VHH-PS with an increased capacity to enter the cell via clathrin-
mediated endocytosis at the expense of a slightly reduced aﬃnity.
These changed properties decreased PDT eﬃcacy, suggesting that as-
sociation with the cell membrane is needed for optimal therapeutic
activity.
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